Last reviewed · How we verify
KL003 Cell Injection Drug Product — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
KL003 Cell Injection Drug Product (KL003 Cell Injection Drug Product) — Kanglin Biotechnology (Hangzhou) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| KL003 Cell Injection Drug Product TARGET | KL003 Cell Injection Drug Product | Kanglin Biotechnology (Hangzhou) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- KL003 Cell Injection Drug Product CI watch — RSS
- KL003 Cell Injection Drug Product CI watch — Atom
- KL003 Cell Injection Drug Product CI watch — JSON
- KL003 Cell Injection Drug Product alone — RSS
Cite this brief
Drug Landscape (2026). KL003 Cell Injection Drug Product — Competitive Intelligence Brief. https://druglandscape.com/ci/kl003-cell-injection-drug-product. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab